Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases-Reference-Cited by-同舟云学术

Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases

Published:2022-07-11 Issue:9 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Relvas Maria¹^ORCID,Figueiredo Ana Carolina¹,Calado Rebeca¹,Calvão Joana¹^ORCID,Ramos Leonor¹

Affiliation:

1. Dermatology Department Coimbra University Hospital Centre Coimbra Portugal

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15678

Reference9 articles.

1. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility

2. Extracutaneous manifestations and complications of inherited epidermolysis bullosa

3. Losartan for treatment of epidermolysis bullosa: A new perspective

4. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms

5. Medical Center – University of Freiburg.A dual‐center prospective phase I/II trial to establish safety tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB). EudraCT Identifier: 2015‐003670‐32.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Skin matrix meets immunomatrix—Implications for genetic and acquired diseases;JEADV Clinical Practice;2024-08-21

2. Treatment of Epidermolysis Bullosa and Future Directions: A Review;Dermatology and Therapy;2024-08

3. Epidermolysis Bullosa: A Review of Wound Care and Emerging Treatments;Current Dermatology Reports;2024-07-30

4. Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects;Therapeutics and Clinical Risk Management;2023-06